SA519401785B1 - تركيبة صيدلانية للوقاية من سرطان الثدي أو علاجه تشتمل على متعدد أشكال بلورية لسداسي أكسيد الزرنيخ الرباعي، وطريقة لإنتاجها - Google Patents
تركيبة صيدلانية للوقاية من سرطان الثدي أو علاجه تشتمل على متعدد أشكال بلورية لسداسي أكسيد الزرنيخ الرباعي، وطريقة لإنتاجهاInfo
- Publication number
- SA519401785B1 SA519401785B1 SA519401785A SA519401785A SA519401785B1 SA 519401785 B1 SA519401785 B1 SA 519401785B1 SA 519401785 A SA519401785 A SA 519401785A SA 519401785 A SA519401785 A SA 519401785A SA 519401785 B1 SA519401785 B1 SA 519401785B1
- Authority
- SA
- Saudi Arabia
- Prior art keywords
- pharmaceutical composition
- breast cancer
- preventng
- crystalline polymorph
- treating breast
- Prior art date
Links
- UYVQXFOBKTWZCW-UHFFFAOYSA-N tetraarsenic Chemical compound [As]12[As]3[As]1[As]32 UYVQXFOBKTWZCW-UHFFFAOYSA-N 0.000 title abstract 3
- 206010006187 Breast cancer Diseases 0.000 title abstract 2
- 208000026310 Breast neoplasm Diseases 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 206010027476 Metastases Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000009401 metastasis Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/36—Arsenic; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/285—Arsenic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01G—COMPOUNDS CONTAINING METALS NOT COVERED BY SUBCLASSES C01D OR C01F
- C01G28/00—Compounds of arsenic
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01G—COMPOUNDS CONTAINING METALS NOT COVERED BY SUBCLASSES C01D OR C01F
- C01G28/00—Compounds of arsenic
- C01G28/005—Oxides; Hydroxides; Oxyacids
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2002/00—Crystal-structural characteristics
- C01P2002/70—Crystal-structural characteristics defined by measured X-ray, neutron or electron diffraction data
- C01P2002/72—Crystal-structural characteristics defined by measured X-ray, neutron or electron diffraction data by d-values or two theta-values, e.g. as X-ray diagram
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2002/00—Crystal-structural characteristics
- C01P2002/70—Crystal-structural characteristics defined by measured X-ray, neutron or electron diffraction data
- C01P2002/77—Crystal-structural characteristics defined by measured X-ray, neutron or electron diffraction data by unit-cell parameters, atom positions or structure diagrams
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2002/00—Crystal-structural characteristics
- C01P2002/80—Crystal-structural characteristics defined by measured data other than those specified in group C01P2002/70
- C01P2002/88—Crystal-structural characteristics defined by measured data other than those specified in group C01P2002/70 by thermal analysis data, e.g. TGA, DTA, DSC
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2006/00—Physical properties of inorganic compounds
- C01P2006/80—Compositional purity
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Inorganic Compounds Of Heavy Metals (AREA)
Abstract
يتعلق الاختراع الحالي بتركيبة صيدلانية pharmaceutical composition للوقاية من سرطان الثدي breast cancer أو علاجه ويشتمل على مركب سداسي أكسيد الزرنيخ الرباعي tetraarsenic hexoxide حيث فيه يكون متعدد أشكال بلورية أ لمركب سداسي أكسيد الزرنيخ الرباعي tetraarsenic hexoxide crystalline polymorph a (As4O6-a)، لمركب سداسي أكسيد الزرنيخ الرباعي بنسبة 99% أو أعلى، وبطريقة لإنتاج هذه التركيبة. تظهر التركيبة وفقًا للاختراع الحالي تأثيرات فائقة لتثبيط انتشار الخلايا السرطانية وانتشارها الثانوي metastasis of cancer cells، بالتالي تكون مفيدة كعامل مضاد للسرطان anticancer agent. شكل1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020160155228A KR101834366B1 (ko) | 2016-11-21 | 2016-11-21 | 육산화사비소의 결정다형을 포함하는 유방암 예방 또는 치료용 약학 조성물 및 이의 제조방법 |
| PCT/KR2017/013148 WO2018093215A1 (ko) | 2016-11-21 | 2017-11-17 | 육산화사비소의 결정다형을 포함하는 유방암 예방 또는 치료용 약학 조성물 및 이의 제조방법 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SA519401785B1 true SA519401785B1 (ar) | 2021-12-14 |
Family
ID=61726934
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SA519401785A SA519401785B1 (ar) | 2016-11-21 | 2019-05-14 | تركيبة صيدلانية للوقاية من سرطان الثدي أو علاجه تشتمل على متعدد أشكال بلورية لسداسي أكسيد الزرنيخ الرباعي، وطريقة لإنتاجها |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US10525079B2 (ar) |
| EP (1) | EP3542803B1 (ar) |
| JP (1) | JP6824432B2 (ar) |
| KR (1) | KR101834366B1 (ar) |
| CN (2) | CN116440161A (ar) |
| AU (1) | AU2017360701B2 (ar) |
| BR (1) | BR112019009483A2 (ar) |
| CA (1) | CA3043153C (ar) |
| CL (1) | CL2019001369A1 (ar) |
| IL (1) | IL266706B (ar) |
| MX (1) | MX2019005736A (ar) |
| MY (1) | MY197198A (ar) |
| PH (1) | PH12019501119A1 (ar) |
| SA (1) | SA519401785B1 (ar) |
| WO (1) | WO2018093215A1 (ar) |
| ZA (1) | ZA201902612B (ar) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA036592B1 (ru) | 2012-06-13 | 2020-11-26 | Инсайт Холдингс Корпорейшн | Замещенные трициклические соединения как ингибиторы fgfr |
| WO2014172644A2 (en) | 2013-04-19 | 2014-10-23 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| ES2895769T3 (es) | 2015-02-20 | 2022-02-22 | Incyte Corp | Heterociclos bicíclicos como inhibidores de FGFR |
| KR101844049B1 (ko) * | 2016-12-05 | 2018-03-30 | 주식회사 케마스 | 육산화사비소의 결정다형을 포함하는 간암 예방 또는 치료용 약학 조성물 |
| KR101844050B1 (ko) | 2016-12-09 | 2018-05-14 | 주식회사 케마스 | 육산화사비소의 결정다형을 포함하는 암 예방 또는 치료용 약학 조성물 |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| CA3099287A1 (en) | 2018-05-04 | 2019-11-07 | Incyte Corporation | Solid forms of an fgfr inhibitor and processes for preparing the same |
| US11174257B2 (en) | 2018-05-04 | 2021-11-16 | Incyte Corporation | Salts of an FGFR inhibitor |
| US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
| WO2021007269A1 (en) | 2019-07-09 | 2021-01-14 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| CR20220169A (es) | 2019-10-14 | 2022-10-27 | Incyte Corp | Heterociclos bicíclicos como inhibidores de fgfr |
| WO2021076728A1 (en) | 2019-10-16 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| EP4069696A1 (en) | 2019-12-04 | 2022-10-12 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| BR112022010664A2 (pt) | 2019-12-04 | 2022-08-16 | Incyte Corp | Derivados de um inibidor de fgfr |
| EP4352059A1 (en) | 2021-06-09 | 2024-04-17 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7261906B2 (en) * | 1998-05-08 | 2007-08-28 | Ill-Ju Bae | Anti-cancer therapy agent of arsenic hexoxide (As4O6) of a natural chemical substance and its pharmaceutical composition |
| KR100272835B1 (ko) | 1998-05-08 | 2000-11-15 | 배일주 | 천연 화학물질 육산화사비소의 신규한 항종양 치료제로서의 용도 및 그 약학적 조성물 |
| KR100399657B1 (ko) * | 2000-06-29 | 2003-09-29 | 배일주 | 혈관신생 억제제 |
| CN1471925A (zh) * | 2002-08-02 | 2004-02-04 | 丛繁滋 | 更适于硬质肿瘤直接给药的含砷组合物、制剂及制备方法 |
| KR100483195B1 (ko) | 2002-08-12 | 2005-04-14 | 배일주 | 육산화사비소를 유효성분으로 함유하는 사상충증예방·치료용 약제학적 조성물 |
| KR101572529B1 (ko) | 2008-11-14 | 2015-11-27 | 배일주 | 암 치료를 위한 육산화사비소의 병용요법 |
| KR101100786B1 (ko) | 2008-12-16 | 2011-12-29 | (주)천지산 | 암에 대한 방사선 치료 증진용 조성물 |
| KR101391148B1 (ko) | 2012-03-29 | 2014-05-07 | 옥은희 | 면역 관련 질환 및 산화적 스트레스 관련 질환의 예방 또는 치료용 조성물 |
| KR101755556B1 (ko) * | 2016-11-18 | 2017-07-07 | 주식회사 케마스 | 육산화사비소의 결정다형을 포함하는 뇌암 예방 또는 치료용 약학 조성물 및 이의 제조방법 |
-
2016
- 2016-11-21 KR KR1020160155228A patent/KR101834366B1/ko active IP Right Grant
-
2017
- 2017-01-24 CN CN202310553812.8A patent/CN116440161A/zh active Pending
- 2017-01-24 CN CN201710060429.3A patent/CN108079018A/zh active Pending
- 2017-11-17 EP EP17872391.2A patent/EP3542803B1/en active Active
- 2017-11-17 JP JP2019547058A patent/JP6824432B2/ja active Active
- 2017-11-17 CA CA3043153A patent/CA3043153C/en active Active
- 2017-11-17 BR BR112019009483A patent/BR112019009483A2/pt unknown
- 2017-11-17 AU AU2017360701A patent/AU2017360701B2/en active Active
- 2017-11-17 US US16/462,011 patent/US10525079B2/en active Active
- 2017-11-17 MX MX2019005736A patent/MX2019005736A/es unknown
- 2017-11-17 WO PCT/KR2017/013148 patent/WO2018093215A1/ko active Application Filing
- 2017-11-17 MY MYPI2019002665A patent/MY197198A/en unknown
-
2019
- 2019-04-25 ZA ZA201902612A patent/ZA201902612B/en unknown
- 2019-05-14 SA SA519401785A patent/SA519401785B1/ar unknown
- 2019-05-19 IL IL266706A patent/IL266706B/en unknown
- 2019-05-20 CL CL2019001369A patent/CL2019001369A1/es unknown
- 2019-05-20 PH PH12019501119A patent/PH12019501119A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3542803A1 (en) | 2019-09-25 |
| JP6824432B2 (ja) | 2021-02-03 |
| US20190328780A1 (en) | 2019-10-31 |
| MX2019005736A (es) | 2019-07-04 |
| US10525079B2 (en) | 2020-01-07 |
| CL2019001369A1 (es) | 2020-02-21 |
| BR112019009483A2 (pt) | 2019-07-30 |
| AU2017360701B2 (en) | 2021-04-01 |
| CN108079018A (zh) | 2018-05-29 |
| ZA201902612B (en) | 2020-11-25 |
| EP3542803A4 (en) | 2020-07-15 |
| WO2018093215A1 (ko) | 2018-05-24 |
| MY197198A (en) | 2023-05-31 |
| AU2017360701A1 (en) | 2019-06-20 |
| IL266706B (en) | 2022-02-01 |
| JP2020503372A (ja) | 2020-01-30 |
| CA3043153A1 (en) | 2018-05-24 |
| KR101834366B1 (ko) | 2018-03-05 |
| IL266706A (en) | 2019-08-29 |
| CN116440161A (zh) | 2023-07-18 |
| CA3043153C (en) | 2021-11-02 |
| PH12019501119A1 (en) | 2019-11-25 |
| EP3542803B1 (en) | 2022-12-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SA519401785B1 (ar) | تركيبة صيدلانية للوقاية من سرطان الثدي أو علاجه تشتمل على متعدد أشكال بلورية لسداسي أكسيد الزرنيخ الرباعي، وطريقة لإنتاجها | |
| SA519401787B1 (ar) | تركيبة صيدلانية للوقاية من سرطان المخ أو علاجه تشتمل على متعدد أشكال بلورية لسداسي أكسيد الزرنيخ الرباعي، وطريقة لتحضيرها | |
| PH12019501292A1 (en) | Pharmaceutical composition for preventing or treating cancer, comprising tetraarsenic hexoxide crystalline polymorph | |
| PH12019501220A1 (en) | Pharmaceutical composition for preventing or treating liver cancer, comprising tetraarsenic hexoxide crystalline polymorph | |
| MX2018012016A (es) | Compuestos biciclicos. | |
| PH12018501226A1 (en) | Methods for treating huntingtons disease | |
| PH12020500033A1 (en) | Macrocyclic compounds and uses thereof | |
| PH12018502535A1 (en) | Substituted carbonucleoside derivatives useful as anticancer agents | |
| MX2022005780A (es) | Moduladores de receptores estrogenicos. | |
| MY196836A (en) | Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (dub) inhibitors | |
| SG10201907164SA (en) | Rna containing composition for treatment of tumor diseases | |
| PH12015502414A1 (en) | Enhancer of zeste homolog 2 inhibitors | |
| MX2016010216A (es) | Composiciones farmaceuticas solidas de antagonistas de los receptores de androgenos. | |
| MX2016016143A (es) | Compuestos de [1,2,4]triazol sustituido. | |
| PH12020500072A1 (en) | Heterocyclic inhibitors of atr kinase | |
| EA033238B1 (ru) | Новые производные тиенопиримидина в качестве ингибиторов nik | |
| MX2019013419A (es) | Compuestos plaguicidas biciclicos. | |
| MX2018016290A (es) | Agente antidesgaste. | |
| WO2019023315A3 (en) | RAC INHIBITORS | |
| PH12019500198A1 (en) | Compounds and compositions and uses thereof | |
| MX2018001315A (es) | Inhibidores de fucosidasa. | |
| SA520411726B1 (ar) | مشتق فينيل بيريدين جديد وتركيبة صيدلانية تشتمل عليه | |
| WO2019036417A3 (en) | Inhibition of ngly1 for the treatment of cancer | |
| IN2014MU00495A (ar) | ||
| CR20190580A (es) | Compuestos de piridina y pirazina |